Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ebb & Flow Focus

After raising the ante, Biogen Idec Inc. is now officially available for sale. Last Friday, the company said it would evaluate whether shareholder value would be best served via an acquisition or remaining as a standalone company.

BIIB (Cambridge, Mass.) also disclosed it had "received expressions of interest, including one from investor Carl Icahn."

The Street has pushed BIIB up steadily from a bottom of about $45 in March, aided by a share buyback via Dutch auction in early

Read the full 792 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers